Core Viewpoint - Mangoceuticals, Inc. has launched two weight-management programs, MangoRx Direct and PeachesRx Direct, allowing patients to access FDA-approved GLP-1 medications from Eli Lilly and Novo Nordisk through its platform [2][4]. Group 1: Program Details - The MangoRx Direct and PeachesRx Direct programs are licensed to issue valid prescriptions for GLP-1 medications, including Zepbound and Wegovy, through a third-party provider [2][5]. - Patients can fill prescriptions at any licensed pharmacy, with the medical operations and prescribing providers vetted by an independent third-party provider [3][5]. - The programs offer telehealth consultations, personalized care plans, and ongoing support for a monthly fee of $99, excluding medication costs [6]. Group 2: Company Overview - MangoRx focuses on men's health and wellness products via a secure telemedicine platform, targeting areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management [7]. - The company aims to provide a smooth telemedicine experience, with prescription requests reviewed by physicians and fulfilled through partner pharmacies [7].

Core Viewpoint - Mangoceuticals (MGRX.US) stock surged approximately 19% pre-market after announcing a collaboration with pharmaceutical giants Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) to provide users with access to their popular GLP-1 weight loss medications [1] Group 1 - The company has launched two platforms, MangoRx Direct and PeachesRx Direct, aimed at self-paying users [1] - The platforms will offer Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) directly to consumers [1]

Core Viewpoint - Mangoceuticals (MGRX.US) stock price surged approximately 19% following the announcement of partnerships with pharmaceutical giants Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) to directly offer their popular GLP-1 weight loss medications [1] Company Summary - Mangoceuticals, based in Dallas, Texas, has launched the MangoRx Direct and PeachesRx Direct platforms aimed at self-paying users [1] - The platforms will sell Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) directly to consumers [1]